Rocket Pharmaceuticals, Inc.
RCKTHealthcareNASDAQBiotechnology · Last scanned Jun 2, 2026
Scan Results
Daily timeframeRocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and. Valued at $329.8M, RCKT is a small-cap name in its sector. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage.
Market Cap
$329.8M
Beta
0.52
P/E (TTM)
—
P/E (Fwd)
-2.60
EPS (TTM)
$-1.87
EPS (Fwd)
$-1.16
ROE
-64.4%
ROA
-35.1%
Cash
$144.4M
Total Debt
$24.8M
Free CF
-$98.9M
52W Change
2.0%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $144.4M in cash comfortably exceeding the $24.8M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$98.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -64.4% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.52 suggests RCKT is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing RCKT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.